LENZ Therapeutics Income Statement (2020-2026) | LENZ

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
5.00M12.50M-12.50M1.90M
Gross Profit (Quarter)
0.82M
Operating items
Research & Development (Quarter)
12.67M8.68M11.21M18.25M17.78M18.30M18.46M10.32M12.64M17.00M19.54M10.54M6.95M6.45M5.87M5.82M9.06M3.79M
Selling, General & Administrative (Quarter)
4.87M5.92M7.74M7.71M9.00M7.85M8.29M2.29M2.32M2.86M5.45M5.55M7.41M6.49M9.36M11.11M12.80M27.60M0.50M44.96M
Other Operating Expenses (Quarter)
-0.07M39.55M1.08M
Operating Expenses (Quarter)
17.53M14.60M18.94M25.96M26.78M26.15M26.75M12.62M14.96M19.86M24.99M16.09M14.35M12.95M15.22M16.93M21.86M31.39M40.05M46.04M
Operating Income (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M
EBIT (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M
Non-operating items
Interest & Investment Income (Quarter)
0.25M1.09M0.85M0.79M2.46M2.74M2.57M2.32M2.25M2.20M2.99M2.64M
Other Non Operating Income (Quarter)
0.00M0.01M0.01M0.12M0.84M1.47M2.15M-0.05M-0.02M-0.10M0.27M-1.35M1.64M-0.01M0.01M-0.01M0.20M-0.01M-0.42M0.00M
Non Operating Income (Quarter)
0.00M0.01M-10.33M0.12M0.84M2.15M-0.05M0.23M-0.10M0.27M-1.35M1.64M2.73M0.01M2.31M0.20M2.19M-7.19M2.65M
Net income details
EBT (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.71M-18.78M-24.14M-15.30M-10.25M-10.21M-12.65M-14.61M-14.41M-16.70M-35.89M-41.49M
Tax Provisions (Quarter)
0.00M0.50M0.00M
Profit After Tax (Quarter)
-17.53M-14.59M-18.93M-25.84M-25.94M-24.68M-24.60M-12.67M-14.73M-18.88M-23.69M-16.65M-10.25M-10.21M-12.65M-14.62M-14.91M-16.70M-35.90M-41.49M
Income from Continuing Operations (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.71M-18.78M-24.14M-15.30M-10.25M-10.21M-12.65M-14.61M-14.91M-16.70M-35.90M-41.49M
Consolidated Net Income (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.71M-18.78M-24.14M-15.30M-10.25M-10.21M-12.65M-14.61M-14.91M-16.70M-35.90M-41.49M
Income towards Parent Company (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.71M-18.78M-24.14M-15.30M-10.25M-10.21M-12.65M-14.61M-14.91M-16.70M-35.90M-41.49M
Net Income towards Common Stockholders (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.71M-18.78M-24.14M-15.30M-10.25M-10.21M-12.65M-14.61M-14.91M-16.70M-35.90M-41.49M
Additional items
EPS (Basic) (Quarter)
-3.45-0.280.06-0.48-0.48-0.45-0.44-6.50-7.53-9.62-12.05-3.53-0.40-0.38-0.41-0.53-0.53-0.59-1.20-1.32
EPS (Weighted Average and Diluted) (Quarter)
-3.45-0.280.06-0.48-0.48-0.45-0.44-6.50-7.53-9.62-12.05-3.53-0.40-0.38-0.41-0.53-0.53-0.59-1.20-1.32
Shares Outstanding (Weighted Average) (Quarter)
4.41M27.38M28.92M54.01M54.57M54.59M58.11M55.86M58.11M1.96M1.96M4.72M15.16M19.20M21.28M27.53M28.08M28.54M28.81M31.35M
Shares Outstanding (Diluted Average) (Quarter)
5.09M20.67M28.92M54.01M54.28M54.59M54.87M1.95M1.96M1.96M1.96M4.72M25.61M19.20M21.28M27.53M27.80M28.05M28.81M31.35M
EBITDA (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.67M-14.74M-18.87M-23.68M-16.66M-10.31M-9.63M-12.98M-14.69M-15.00M-16.51M-35.88M-42.18M
Interest Expenses (Quarter)
Shares Outstanding (Quarter)
55.98M58.08M58.01M58.01M58.21M58.15M1.95M1.95M1.96M1.96M1.97M25.50M25.85M27.48M27.52M27.54M28.50M28.59M31.34M31.35M
Tax Rate (Quarter)
-0.01-3.47-0.01